Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels

5. august 2026 oppdatert av: Artah Nutrition Limited

This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. The trial is a single-arm, unblinded, virtual study in which all 50 participants will use the test product daily for 4 weeks.

Participants will complete self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4, and will undergo cognitive battery testing at Baseline and Week 4. The primary endpoint is change in cognitive performance scores as measured by a standardized cognitive battery. Secondary endpoints include participants' self-reported perceptions of mental clarity, alertness, mood, physical performance, overall energy levels, and frequency of food cravings.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

50

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89101
        • Citruslabs

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Be male or female.
  • Be aged 25-60.
  • Anyone currently experiencing mild to moderate issues with at least three of the following: low energy or fatigue
  • difficulty concentrating or low mental sharpness
  • experiences of brain fog or lack of mental clarity
  • feeling of low productivity
  • muscle weakness
  • unwanted food cravings.
  • Undertakes moderate to high-intensity exercise such as jogging/running and/or heavy resistance training at least three times per week.
  • Willing to refrain from taking any products, medications, or supplements that target energy, cognition, or physical performance during the test period.
  • Anyone with a BMI 18.5 to 30.
  • Anyone who has access to a device (e.g., smartphone, laptop, computer) for reliable internet.
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • Anyone willing to maintain a consistent diet and physical activity throughout study duration.

Exclusion Criteria:

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Anyone suffering from gastrointestinal disorders including but not limited to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and celiac disease.
  • Anyone suffering from hyperkalemia (high potassium), liver disease, or kidney disease.
  • Anyone taking ACE inhibitors or potassium-sparing diuretics, examples include: Spironolactone (Aldactone), Eplerenone (Inspra), Amiloride (Midamor), Triamterene (Maxzide), Lisinopril (Zestril, Prinivil), Enalapril (Vasotec), Ramipril (Altace), Benazepril (Lotensin), Quinapril (Accupril), Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), Lithium carbonate (Lithobid, Eskalith).
  • Anyone taking antibiotics.
  • Anyone with any allergies or sensitivities to any of the study product ingredients.
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
  • Anyone unwilling to follow the study protocol.
  • Anyone with a history of substance abuse.
  • Anyone who is a shift worker with an irregular sleep-wake cycle.
  • Anyone who drinks heavily (8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
  • Anyone who is currently a smoker or has been a smoker in the past 3 months.
  • Currently partaking in another research study, or planning to at any point during this study's duration.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Cellular Hydration Supplement
Kosttilskudd: Cellular Hydration Supplement
All 50 participants receive the Artah Cellular Hydration electrolyte supplement taken twice daily (once in the morning before the first meal and once in the afternoon after lunch or before evening exercise) as one teaspoon (approximately 7 g) stirred into 750 ml of water for 4 weeks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Cognitive Battery Test Score (Polygons)
Tidsramme: Baseline and Week 4
Change in processing speed and information sorting ability assessed via the Polygons timed cognitive battery subtest
Baseline and Week 4
Change in Cognitive Battery Test Score (Double Trouble)
Tidsramme: Baseline and Week 4
Change in selective attention and processing speed assessed via the Double Trouble timed cognitive battery subtest (Stroop-based)
Baseline and Week 4
Change in Cognitive Battery Test Score (Feature Match)
Tidsramme: Baseline and Week 4
Change in focus and processing speed assessed via the Feature Match timed cognitive battery subtest
Baseline and Week 4
Change in Cognitive Battery Test Score (Paired Associates)
Tidsramme: Baseline and Week 4
Change in memory recall assessed via the Paired Associates performance-based cognitive battery subtest
Baseline and Week 4
Change in Cognitive Battery Test Score (Digit Span)
Tidsramme: Baseline and Week 4
Change in short-term memory and cognitive flexibility assessed via the Digit Span performance-based cognitive battery subtest
Baseline and Week 4
Change in Cognitive Battery Test Score (Spatial Planning)
Tidsramme: Baseline and Week 4
Change in executive function and logical decision-making assessed via the Spatial Planning timed cognitive battery subtest
Baseline and Week 4

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Self-Reported Mental Clarity and Focus
Tidsramme: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Alertness
Tidsramme: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Mood
Tidsramme: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Physical Performance
Tidsramme: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Overall Energy Levels
Tidsramme: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Frequency of Food Cravings
Tidsramme: Baseline, Week 1, Week 2, Week 3, and Week 4
Assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 3, and Week 4

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Artah Nutrition Limited

Samarbeidspartnere

Citruslabs

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. juni 2025

Primær fullføring (Faktiske)

16. august 2025

Studiet fullført (Faktiske)

16. august 2025

Datoer for studieregistrering

Først innsendt

5. august 2026

Først innsendt som oppfylte QC-kriteriene

5. august 2026

Først lagt ut (Faktiske)

10. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 20772
  • legacy-20772

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere